Passage Bio

PASG

Market cap $15.5M

PASG Hedge Fund Activity: Q1 2026 in Review

35 of the 8,126 institutional investors tracked by Wall St. Rank reported a position in Passage Bio (PASG) for Q1 2026, worth a combined $13.8M — down 26% from $18.6M a quarter earlier.

Buyers outnumbered sellers: 12 funds opened new PASG positions and 6 closed out — a net gain of 6 holders — while 6 added to existing stakes and 4 trimmed.

The largest buyer was Ikarian Capital, opening a new position worth an estimated $705K. The largest seller was Citadel Advisors, exiting entirely with an estimated $208K sold.

• 35 institutional investors held Passage Bio (PASG) as of Q1 2026, up from 30 in Q4 2025.
• Funds reported $13.8M of Passage Bio stock for Q1 2026, down 26% quarter-over-quarter.
• 12 funds opened new Passage Bio positions in Q1 2026 and 6 closed out, a net change of +6 holders.
• The largest Passage Bio buyer in Q1 2026 was Ikarian Capital, an estimated $705K added.
• The largest Passage Bio seller in Q1 2026 was Citadel Advisors, an estimated $208K sold.

Based on aggregated 13F filings for Q1 2026.